Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

limited therapeutic choices."

The picoplatin data will be presented in a poster session on Friday, February 27, at 11:45 a.m. Eastern Time (abstract #186/poster #A38) during the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla. Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of solid tumors.

Phase 2 CRPC Trial Design and Results to Date

Patient enrollment in the ongoing Phase 2 trial of picoplatin in patients with metastatic CRPC was completed in December 2007. The trial enrolled 30 patients with metastatic CRPC who had not received prior chemotherapy. The objective of the study is to evaluate the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every three weeks in combination with full doses of docetaxel (75 mg/m squared) with daily prednisone (5 mg) as a first-line treatment. PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint; secondary endpoints include safety, radiologic response, time to progression and overall survival.

The latest trial findings, scheduled for presentation at the ASCO 2009 GU Symposium, demonstrated that:

  • Reductions of PSA levels of at least 50 percent were achieved in 21 of 27 (78 percent) evaluable patients who received picoplatin in combination with docetaxel and prednisone. In contrast, data from published literature report PSA responses of approximately 45 percent in patients who received docetaxel/prednisone.
  • To date, the median time to PSA progression is 8.5 months with picoplatin in combination with docetaxel and prednisone.
  • Radiologic response
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at Dallas ... in Phoenix, AZ , today announce an ... for patients with a broad range of cancers. Aligning the ... trials and access to technology to drive the development of ... across Baylor Scott & White Health,s 49 hospitals ...
(Date:5/21/2015)... N.J. (PRWEB) May 21, 2015 ... circulation audit and been admitted to BPA Worldwide ... BPA Worldwide will track audience data for Specialty ... coverage. , “By becoming a member of ... dedication to providing our clients with the most ...
(Date:5/21/2015)... 21, 2015 uBiome, the leading ... partnership with PicnicHealth, a healthcare company that collects ... with Inflammatory Bowel Disease (IBD) will receive a ... uBiome research kit. Both companies were funded by ... , For more information on this partnership and ...
(Date:5/21/2015)... Worms, Germany (PRWEB) May 21, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent subsidiary of the International Pharmaceutical ... three Grace facilities that produce its SYLOID® FP ... now received GMP certification, following the Curtis Bay, ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Specialty Pharmacy Times Joins BPA Worldwide 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... Nov. 25 /PRNewswire/ - The Atlantica BioEnergy Task Force ... with political, business and education leaders from across Atlantic ... the forestry sector. , "The global forest ... all stakeholders to look for environmentally sustainable ways to ...
... 25 BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today ... a company update at the Piper,Jaffray Healthcare Conference in New ... , Interested parties may ... investor section of the BioMarin website, http://www.BMRN.com . A,replay ...
... Meet Dr. David Onslow, owner of,Excellon, a biotech company ... his team of scientists rise to the top with the ... about a,mysterious night in the 1970s when he witnessed a ... his wife Kate, and a team of doctors at,the foot ...
Cached Biology Technology:Atlantica Bioenergy Task Force hosts industry and government leaders 2Atlantica Bioenergy Task Force hosts industry and government leaders 3BioMarin to Present at the Piper Jaffray Healthcare Conference 2'Far From Beyond': A Glimpse into the World of Biotechnology and the Future of the Free World 2
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... 2015  Through a well-rounded UAS delegation representing private industry, ... strong showing at AUVSI,s Unmanned 2015 conference last week in ... Ohio,s UAS industry met with over 200 hundred ... along the UAS ecosystem. "Our message is ... for Aerospace Rich Knoll . "If you want to ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... unknown mechanism in the body which regulates a hormone ... of blood pressure, pain and appetite. The breakthrough could ... problems connected with these functions in the future. ... London found that lactate essentially lactic acid ...
... scientists at King,s College London have identified a gene linking ... intelligence. The study is published today in Molecular Psychiatry ... forms of intellectual impairment. The researchers looked at ... It is known as ,grey matter, and plays a key ...
... used to treat breast cancer, also kills a fungus that ... findings, which could lead to new treatments for a disease ... mBio , the online open-access journal of the American Society ... additional animal studies to see if tamoxifen can be used ...
Cached Biology News:New research sheds light on how the body regulates fundamental neuro-hormone 2Scientists identify gene linking brain structure to intelligence 2Breast cancer drug fights fungal disease 2
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Recombinant Rat Fas Ligand/TNFSF6...
Request Info...
FGF Receptor 1 Antibody...
Biology Products: